Who Exports Enalapril from India — 261 Suppliers Behind a $235.3M Market
India's enalapril export market is supplied by 261 active exporters who collectively shipped $235.3M across 3,403 shipments. MYLAN LABORATORIES LIMITED leads with a 83.8% market share, followed by IPCA LABORATORIES LIMITED and J B CHEMICALS AND PHARMACEUTICALS LIMITED. The top 5 suppliers together control 91.5% of total export value, reflecting a concentrated market structure.
Top Enalapril Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading enalapril exporter from India, holding a 83.8% share of the $235.3M market across 3,403 shipments from 261 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, IPCA LABORATORIES LIMITED, J B CHEMICALS AND PHARMACEUTICALS LIMITED, AUROBINDO PHARMA LTD, WEXFORD LABORATORIES PRIVATE LIMITED — collectively control 91.5% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (83.8%), IPCA LABORATORIES LIMITED (2.9%), J B CHEMICALS AND PHARMACEUTICALS LIMITED (2.0%), AUROBINDO PHARMA LTD (1.7%), WEXFORD LABORATORIES PRIVATE LIMITED (1.1%).
Top Enalapril Exporters from India
Ranked by export value · 261 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED ENALAPRIL TABLETS 20 MGENALAPRIL TABLETS 5 MGHARMLESS MEDICINES, ENALAPRIL TABLETS 20 | $197.1M | 4 | 83.8% |
| 2 | IPCA LABORATORIES LIMITED HARMLESS MEDICINES:ENALAPRIL MALEATE 10MG TABLETSPHARMAPRESS 10MG TABLETS 28 S PACKHARMLESS MEDICINES ENALAPRIL MALEATE 1 | $6.8M | 5 | 2.9% |
| 3 | J B CHEMICALS AND PHARMACEUTICALS LIMITED ENALAPRIL MALEATE TABLETS USP 20 MG (ENAPHARMAPRESS 10MG TABLETS 28 S PACKENALAPRIL MALEATE SOLUTION | $4.8M | 5 | 2.0% |
| 4 | AUROBINDO PHARMA LTD ENALAPRIL MALEATE TABLETS 20MG(ENALAPRILENALAPRIL TABLETS 20MG(ENALAPRIL GENERISENALAPRIL MALEATE TABLETS 10MG(ENALAPRIL | $4.0M | 4 | 1.7% |
| 5 | WEXFORD LABORATORIES PRIVATE LIMITED ENALAPRIL MALEATE TABLETS USP 20MGENALAPRIL MALEATE TABLETS USP 10MG | $2.5M | 4 | 1.1% |
| 6 | KOPRAN LIMITED PHARMAPRESS 10MG TABLETS 28 S PACKHARMLESS MEDICINES ENALAPRIL MALEATE 1ENALAPRIL MALEATE TABLETS USP 10MG.EACH | $1.5M | 4 | 0.6% |
| 7 | ALPHAMED FORMULATIONS PRIVATE LIMITED PHARMAPRESS 10MG TABLETS 28 S PACKHARMLESS MEDICINES ENALAPRIL MALEATE 1ENALAPRIL MALEATE TABLETS USP 10MG.EACH | $1.4M | 1 | 0.6% |
| 8 | MICRO LABS LIMITED HARMLESS MEDICINES, ENALAPRILMALEAAT/HYDPHARMA DRUGS & MEDI ENALAPRIL 5MG 10X10TENALAPRIL HCT TAB 20 12.5MG 100BL D/S MYPACKS 20846 | $1.3M | 4 | 0.5% |
| 9 | EMIL PHARMACEUTICAL INDUSTRIES PVT LTD ENALAPRIL MALEATO 20MG. X 1000 COMPENALAPRIL MALEATO 20MG X 1000 COMP E | $1.2M | 2 | 0.5% |
| 10 | CADILA PHARMACEUTICALS LIMITED PHARMAPRESS 10MG TABLETS 28 S PACKHARMLESS MEDICINES ENALAPRIL MALEATE 1ENALAPRIL MALEATE TABLETS USP 10MG.EACH | $1.1M | 15 | 0.5% |
| 11 | INTAS PHARMACEUTICALS LIMITED HARMLESS MEDICINES, ENALAPRILMALEAAT/HYDPHARMA DRUGS & MEDI ENALAPRIL 5MG 10X10TENALAPRIL HCT TAB 20 12.5MG 100BL D/S MYPACKS 20846 | $1.1M | 12 | 0.5% |
| 12 | BIOMATRIX HEALTHCARE PRIVATE LIMITED ENALAPRIL MALEATE TABLETS USP 20 MG (ENAENALAPRIL MALEATE TABLETS USP 10 MG (ENAENALAPRIL MALEATE TABLETS USP 20MG UNITS:6X10 TAB | $1.1M | 2 | 0.5% |
| 13 | MEDOPHARM HARMLESS MEDICINES, ENALAPRILMALEAAT/HYDPHARMA DRUGS & MEDI ENALAPRIL 5MG 10X10TENALAPRIL HCT TAB 20 12.5MG 100BL D/S MYPACKS 20846 | $1.0M | 12 | 0.4% |
| 14 | SUN PHARMACEUTICAL INDUSTRIES LIMITED PHARMAPRESS 10MG TABLETS 28 S PACKHARMLESS MEDICINES ENALAPRIL MALEATE 1ENALAPRIL MALEATE TABLETS USP 10MG.EACH | $1.0M | 3 | 0.4% |
| 15 | ANNORA PHARMA PRIVATE LIMITED ENALAPRIL MALEATE SOLUTIONENALAPRIL MALEATE MG SOLUTIONENALAPRILAT INJECTION USP 2.5MG/2ML | $969.3K | 1 | 0.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Enalapril exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| MYLAN LABORATORIES LIMITED | Warning Letter, December | Yes, as of March 202 | Unknown | Not verified | FDA issued a warning letter in December 2024; WHO conducted a for-cause inspecti |
| MICRO LABS LIMITED | Unknown | Yes, as of February | Unknown | Not verified | WHO conducted inspections in August 2024 and February 2025 at various facilities |
| MEDOPHARM PRIVATE LIMITED | Unknown | Yes, as of January 2 | Unknown | Not verified | WHO conducted an inspection in January 2025 at the Kayarambedu Village facility. |
| CADILA PHARMACEUTICALS LIMITED | Warning Letter, March 201 | Yes | Unknown | Not verified | FDA issued a warning letter in March 2014 for the Ankleshwar facility. |
| INTAS PHARMACEUTICALS LIMITED | Warning Letter, December | Yes | Yes | Not verified | FDA issued a warning letter in December 2022 for the Sanand facility. |
| IPCA LABORATORIES LIMITED | Unknown | Yes | Yes | Not verified | Company has received WHO-GMP and EU GMP certifications. |
| AUROBINDO PHARMA LTD | Approved | Yes | Yes | 89 | Company has received multiple FDA approvals and holds 89 ANDAs. (extranet.who.in |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | 70 | Company has received multiple FDA approvals and holds 70 ANDAs. (extranet.who.in |
| J B CHEMICALS AND PHARMACEUTICALS LIMITED | Approved | Yes | Yes | 45 | Company has received multiple FDA approvals and holds 45 ANDAs. (extranet.who.in |
| KOPRAN LIMITED | Approved | Yes | Yes | 30 | Company has received multiple FDA approvals and holds 30 ANDAs. (extranet.who.in |
TransData Nexus reviewed the regulatory standing of 10 leading Enalapril exporters from India. 4 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 6 are EU GMP compliant. 3 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Enalapril sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as "India's pharmaceutical capital," has been a central hub for bulk drug manufacturing since the establishment of Indian Drugs and Pharmaceuticals Limited (IDPL) in 1961. The city contributes significantly to India's bulk drug production, manufacturing one-third of the nation's bulk drugs and 16% of biotechnology products as of 2010. This robust infrastructure supports the synthesis of active pharmaceutical ingredients (APIs) like Enalapril, ensuring a steady supply for both domestic formulations and international exports.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara being pivotal cities in this landscape. Vadodara, for instance, is home to Alembic Pharmaceuticals, established in 1907, which has evolved into a major player in the pharmaceutical industry. These cities host numerous companies specializing in the production of finished dosage forms, including Enalapril tablets, catering to both domestic and international markets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the export of pharmaceuticals to global markets. This region houses several pharmaceutical companies with manufacturing units that produce a wide range of drugs, including Enalapril, ensuring efficient distribution channels for international shipments.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. This area attracts numerous pharmaceutical companies that produce various formulations, including Enalapril, benefiting from cost advantages that can be passed on to consumers.
5Sourcing Recommendations
- Diversify Supplier Base: While MYLAN LABORATORIES LIMITED dominates Enalapril exports with 83.8% market share, consider engaging with other suppliers like IPCA LABORATORIES LIMITED and J B CHEMICALS AND PHARMACEUTICALS LIMITED to mitigate supply chain risks.
- Leverage Regional Specializations: Source APIs from Hyderabad's bulk drug manufacturers and formulations from the Ahmedabad-Vadodara corridor to capitalize on regional expertise and infrastructure.
- Optimize Export Logistics: Utilize the Mumbai-Thane-Raigad region's export facilities to streamline international shipments of Enalapril, ensuring timely delivery to key markets such as Hungary and South Africa.
- Explore Cost Benefits: Consider sourcing from the Baddi-Nalagarh region to take advantage of tax incentives, potentially reducing procurement costs for Enalapril formulations.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Enalapril exporters from India
Aurobindo Pharma Ltd — Aurobindo Pharma acquires remaining stake in GLS Pharma
Aurobindo Pharma Ltd completed the acquisition of the remaining 49% stake in GLS Pharma, a Hyderabad-based oncology company, thereby gaining full ownership. - IMPACT: This acquisition is expected to enhance Aurobindo's oncology portfolio, potentially influencing its strategic focus and resource allocation, which may indirectly affect its Enalapril export operations.
Impact: This acquisition is expected to enhance Aurobindo's oncology portfolio, potentially influencing its strategic focus and resource allocation, which may indirectly affect its Enalapril export operations.
Viatris (formerly Mylan Laboratories Limited) — Viatris divests certain businesses for $3.6 billion
Viatris announced the divestiture of select businesses for $3.6 billion as part of its ongoing strategic realignment. - IMPACT: The divestiture may lead to changes in Viatris's operational focus, potentially impacting its Enalapril production and export strategies.
Impact: The divestiture may lead to changes in Viatris's operational focus, potentially impacting its Enalapril production and export strategies.
Viatris (formerly Mylan Laboratories Limited) — US FDA restricts imports from Viatris's India facility
The US Food and Drug Administration imposed import restrictions on certain products manufactured at Viatris's facility in India due to quality control and data integrity issues. - IMPACT: These regulatory actions could disrupt Viatris's supply chain, potentially affecting the availability and export of Enalapril to key markets.
Impact: These regulatory actions could disrupt Viatris's supply chain, potentially affecting the availability and export of Enalapril to key markets.
Common Questions — Enalapril Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which enalapril supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 91 recorded shipments worth $197.1M. IPCA LABORATORIES LIMITED (123 shipments) and J B CHEMICALS AND PHARMACEUTICALS LIMITED (361 shipments) are also established high-volume exporters.
Q How many enalapril manufacturers are there in India?
India has 261 active enalapril exporters with a combined export market of $235.3M across 3,403 shipments to 115 countries. The top 5 suppliers hold 91.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for enalapril from India?
Average FOB unit price: $5.32 per unit, ranging from $0.00 to $1024.25. Average shipment value: $69.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 261 verified Indian exporters of Enalapril ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,403 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 115 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,403 Verified Shipments
261 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists